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Abstract
Platelets are small, anucleated cells that participate in primary hemostasis by forming a hemostatic 
plug at the site of a blood vessel’s breach, preventing blood loss. However, hemostatic events can 
lead to excessive thrombosis, resulting in life-threatening strokes, emboli, or infarction. 
Development of multi-scale models coupling processes at several scales and running predictive 
model simulations on powerful computer clusters can help interdisciplinary groups of researchers 
to suggest and test new patient-specific treatment strategies.
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Multiple Functions of Platelets in Blood Clot Development
First observed through simple microscopy in the nineteenth century, platelets and leukocytes 
interact with blood vessel walls [1, 2]. Since those first observations, an impressive body of 
information has accumulated to establish the centrality of platelets in vascular thrombosis. 
The main steps in thrombosis formation classically include the tethering, rolling/
translocation, and adhesion of leukocytes and platelets to the exposed matrix at the damaged 
blood vessel site. Arterial thrombosis remains the most common cause of myocardial 
infarction and stroke, resulting in significant morbidity and mortality. To prevent thrombosis, 
many patients are treated with antiplatelet agents [3]. By producing chemical messengers, 
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microparticles, and vascular changes, platelets also promote cancer and inflammation [4–6]. 
Therefore, there is a great need to understand more platelet–leukocyte–endothelial 
interactions (Fig. 5.1) and translate that into more effective, less toxic therapies.
A major challenge in quantitative understanding of hemostasis/thrombosis is to integrate 
various processes occurring during thrombus development. To predict how variations of 
multiple factors associated with platelet activity affect thrombus development is of great 
biomedical importance. However, there are significant challenges in developing such 
understandings. For instance, platelet–vessel wall receptor–ligand interactions occur at 
nanometer scale, whereas blood flow dynamics in the vicinity of a thrombus is a 
macroscopic event developing over the scale of hundreds of micrometers to millimeters. 
Coupling various processes is a complex, challenging task.
By reviewing main platelet functions, their roles in hemostasis/thrombosis, and 
computational approaches to simulate clotting events, this chapter establishes a rationale for 
a systems approach to platelet physiology. These include modeling of coagulation reactions, 
platelet activation, platelet dynamics, platelet–platelet interactions, and blood flow. The 
integrative modeling approaches are described to provide the basis for multi-scale 
computational models of thrombus development. First, biological background on platelet 
functioning is given, including platelet adherence and activation, intracellular and 
extracellular signaling, relation to tumor metastasis, and global approaches to study platelet–
vessel wall interactions. Then, several recent integrative modeling methods of thrombus 
development involving cellular signaling, platelet–platelet, platelet–flow, and platelet–wall 
interactions are highlighted. Finally, a concluding perspective is offered on the role of 
platelets in hemostasis/thrombosis and tumor progression as well as the role of system 
biology in testing new therapeutic targets.
Platelet Adherence and Activation
Platelets interact with their environment through specialized receptors, many of which are 
integrins [7]. One principle mediator is platelet P-selectin (CD62P), a cell adhesion 
molecule stored in platelet alpha granules that interacts with P-selectin ligand 1 (PSGL-1, or 
CD162, found on leukocytes and endothelial cells). Endothelial cells possess granules called 
Weibel–Palade bodies, which release von Willebrand Factor (vWF) and P-selectin when 
activated. Interaction between P-selectin and its ligand occurs during tethering and rolling on 
the endothelium [1]. Importantly, the platelet surface receptor for vWF is glycoprotein Ib 
(GPIb; CD42). Lack of cleavage of high molecular weight vWF multimers results in 
thrombotic thrombocytopenic purpura, a catastrophic disorder. On the other hand, defective 
GPIb expression or activity results in excessive bleeding, the Bernard–Soulier disorder. vWF 
binding to GPIb induces downstream cytoskeletal actin rearrangement via FilaminA. 
FilaminA which regulates intracellular signaling [8] is responsible for a solid anchorage of 
GPIb [9]. Filamin A mutations have recently been found as a cause for thrombocytopenia 
[10] and abnormal platelet function [11].
Another critical mediator for platelet interactions is integrin αIIbβ3 (CD41), a cell surface 
receptor for fibrinogen. This integrin is defective in individuals suffering from Glanzmann’s 
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thrombasthenia, a bleeding disorder. When fibrinogen binds to the integrin, a cascade of 
downstream events, which include cytoskeletal rearrangements via talin and other signaling 
involving rous sarcoma (SRC) and focal adhesion kinase (FAK)-tyrosine kinases [12], is set 
in motion. Equally important is the presence of collagen receptors at the surface of the 
platelet, the better known of which are GPVI and α2β1. GPVI in particular seems to have a 
prominent role during collagen exposure to platelet surface and subsequent activation [12]. 
Platelets also express the C-type lectin receptor (CLEC-2, which triggers a downstream 
signaling cascade similar to that of GPVI, including activation of the spleen tyrosine kinase 
(Syk)) [12].
G-protein-coupled receptors include the thrombin receptor, adenosine diphosphate (ADP) 
receptors (P2Y1, P2Y12 which is a target for several “antiplatelet” drugs in thrombotic 
disease treatment) [3, 13], and thromboxane A2 receptor. They are activated in response to 
soluble factors from the blood. Exposure of the subendothelial matrix provides additional 
potent activators of platelet activation and coagulation. Platelet receptors recognize matrix 
components, collagen (via α2β1, GPVI), and laminin (via α6β1). Targeting of the laminin 
receptor, like the integrin α6β1, has been shown to be a promising strategy in the treatment 
of arterial thrombosis [14]. Recently, platelets were found to express CXCR6, the receptor 
specific to chemokine CXCL16. CXCL16 present on atherosclerotic lesions was found to 
enhance platelet adhesion to the endothelium after high arterial shear stress and to injured 
vascular wall [15]. Other cell surface proteins on platelets, such as Eph kinases and 
EphrinB1 [16], semaphorins [17] or Gas6 receptors [18], may promote thrombus formation. 
Gap junction channels, such as connexin 37 [19], may also enhance thrombus formation.
The list of platelet cell surface receptors or adhesion molecules will likely continue to grow, 
adding to complexity of platelet interactions and function. For instance, by expressing 
CD40-L, Fc receptors to immunoglobulins, and toll-like receptors [5], platelets serve as 
effectors in the immune system. Platelet-derived microparticles containing pro-inflammatory 
cytokines such as IL-1β contribute to inflammation [6].
Intracellular Cell Signaling and Inter-platelet Signaling
Resulting from those diverse ligand–receptor stimuli (Fig. 5.2), downstream signaling events 
involve phospholipid metabolism, generation of cAMP and cGMP second messengers, and 
Ca2+ release from the dense tubular system. These pathways lead to cytoskeletal 
reorganization, calpain activation, and signal amplification and diversification due to protein 
and lipid kinases. Phosphatase activity increases too [20]. Many of these pathways intersect 
or interact with each other in a complex fashion. Besides outside–inside signaling, there is 
also inside–outside signaling, as in the case of αIIbβ3 integrin activation [12, 21].
Extraplatelet Signaling
Upon platelet stimulation, alpha or dense granule release occurs, leading to platelet 
activation amplification, since the released substances (fibrinogen, vWF,ADP, thromboxane 
A2, thrombospondin-1) will further activate platelets and contribute to hemostasis. One 
adaptive measure is to induce blood vessel constriction, which is achieved through 
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thromboxane A2. However, alpha granules release not only prothrombotic but also pro-
angiogenic (VEGF) and anti-angiogenic (endostatin, thrombospondin) factors [22–25]. 
Intensively studied are platelet microparticles and exosomes. Microparticles are shed from 
membranes and their size varies from 100 to 1000 nm [26], while exosomes are secreted and 
overall smaller (30–100 nm) [27]. Microparticles are shed from the platelet membrane and 
carry tissue factor activity, thus being procoagulant [12, 28]. Exosome secretion from 
platelets has also been described, but their role is less well known [29]. Inflammation 
contributes to thrombus formation through the interaction of platelets with leukocytes 
(neutrophils and monocytes) [30, 31]. Indeed, thrombosis could more generally be seen as 
an effector of innate immunity [32]. Moreover, neutrophils also contribute to thrombus 
formation, including via formation of neutrophil extracellular traps (NET) [33–37].
When a blood vessel is injured, the subendothelial matrix is exposed, and matrix 
components such as the collagens or laminins serve as potent activators of platelet 
activation. Furthermore, endothelial cells release prothrombotic factors such as vWF from 
their Weibel–Palade bodies. Interestingly, vWF release from the endothelial Weibel–Palade 
bodies is dependent on essential autophagy genes Atg5 or Atg7, and pharmacological 
inhibitors of autophagic flux lead to increased bleeding time [38]. On the other hand, the 
endothelium also releases substances that are inhibitory to platelet activation, by secreting 
nitric oxide (NO) and the downstream modulation of cGMP levels [39–43], or by secreting 
prostacyclin(PGI2) [44].
On a different scale, platelet contraction forces depend on microenvironment stiffness [45] 
and platelet adhesion and spreading depends on local microenvironment geometry [46]. 
Stresses developed by contracting platelets significantly alter thrombus internal structure and 
were recently shown to strongly deform embedded erythrocytes [47]. Vessels can be made 
susceptible to injury depending on vessel geometry, biophysical and rheological forces from 
the blood flow that will produce turbulence and shear. Models are being developed, where 
the role of vWF is still being found to be crucial [48]. Progression of an injured 
endothelium, resulting from a combination of flow shear, inflammatory state, and 
dyslipidemia, results in atherosclerosis and atheroma plaques, which by themselves lead to 
specific atheroma–platelet interactions [15, 44].
Platelets and Tumor Metastasis Through the Vessel Wall
Apart from their role in thrombosis and inflammation/immunity, platelets are also currently 
under intense scrutiny for their role in cancer metastasis dissemination. Indeed, a study has 
found that interactions between platelets and tumor cells induce an invasive mesenchymal-
like phenotype and enhance in vivo metastasis. This effect is mediated by platelet-derived 
TGFβ, which activates the Smad and NF-κB pathways in cancer cells [4]. Specific to vessel 
wall effects, tumor cell-activated platelets secreted ADP, which facilitates cancer cell 
penetration past blood vessels. The P2Y2 receptor on blood vessel cells is necessary for this 
effect [49].
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Global Approaches in Studying Platelet–Vessel Wall Interactions
To discover molecular mechanisms of platelet interactions with the vessel wall, researchers 
have been relying on narrowed and focused approaches (Fig. 5.3). One example is observing 
human disease and trying to pin down the molecular defect. Then one might want to search 
for partners of known actors. Subsequently, to confirm the relevance, one might pursue on 
knocking down or knocking out an element and observing the cell or organism for modified 
behaviors. More recently, researchers have been adding new global approaches in the field of 
biology, enriching knowledge through global and systemic approaches [50]. These new 
global approaches include:
1. Mutagenesis screening by N-ethyl-N-nitrosourea (ENU). For example, BcL-xL 
was discovered to regulate platelet half-life or platelet number [51].
2. Genome-wide association studies (GWAS). Human genomic variations are 
associated with cardiovascular outcomes, platelet size, or number, as reported by 
European study consortiums [52]. Jones et al. found that single nucleotide 
variants in platelet endothelial aggregation receptor 1 (PEAR1), guanine 
nucleotide exchange factors (GEFs) for Rho family GTPases (VAV3), and IP3 
receptor (ITPR1) were associated with modified platelet response to platelet 
agonists [53].
3. Transcriptomics. Rowley et al. recently reported a comprehensive transcriptome 
study of human and mouse platelets [54]. This approach led to the discovery of 
connexin 37 in platelet aggregation [19].
4. Proteomics. Comprehensive platelet proteomics have been performed [55] and 
can be further narrowed down to subfields as “secretome” or “phosphoproteome” 
[56]. These proteomic studies revealed that secretogranin III, cyclophilin A, and 
calumenin were secreted by platelets after thrombin stimulation and found in 
atherosclerotic plaques [57] and nitrous oxide-treatment abrogated platelet 
activation by thrombin and prevented thrombin-induced translocation of gelsolin, 
filamin, 14–3-3 ζ, phosphatidylinositol 3-kinase-gamma isoform, and growth 
factor receptor-bound protein 2 (Grb2) [58].
5. Network analysis. Network analysis tools are being developed and databases are 
being made available online. For example, cPlateletWeb (http://
plateletweb.bioapps.biozentrum.uni-wuerzburg.de) is an Internet-based platform 
organizing signaling network [59, 60]. A study based on PlateletWeb found a 
novel interaction between vasodilator-stimulated phosphoprotein and Abelson 
interactor 1 in human platelets [61]. Another database is Reactome (http://
www.reactome.org), where extensive data have been collected, analyzed, and 
grouped in different pathways [62].
6. Informatics for modeling and simulations. Bioinformatics can be used to develop 
models for simulating platelet function, thrombus formation associated with pro- 
or anticoagulant gradients, and different flow conditions [63–69]. Indeed, 
thrombus formation studies have mostly focused on separate components of 
thrombogenesis, which can be numerous and subgrouped into categories: 
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coagulation cascades of blood coagulation factors, platelet adhesion to the 
vascular wall, platelet aggregation among themselves, internal platelet activation 
phenomena, platelet substance release and amplification reaction, white blood 
cells’roles in thrombus formation, vessel wall product release, vessel wall injury 
and exposure of thrombogenic elements, atheroma genesis, and blood flow shear 
variation and impact.
Integrative Multi-scale Modeling Approaches
Integrating the relative role of each of the mentioned elements to model thrombus formation 
has been challenging. Various modeling approaches have been proposed, that integrate a 
certain number of processes or scales, and tested with the assistance of simulations 
implemented on large computer clusters (see [63, 65, 70, 83] for review). One target goal for 
future research would be to improve modeling ability to predict platelet/vessel wall behavior 
and thrombus formation by integrating simulations of the molecular signature 
characteristics, mechanical properties of agonist/antagonist, blood flow and viscoelastic 
properties of a blood vessel. Below we outline several existing modeling approaches that 
combine several scales.
Explicit incorporation of single platelet dynamics into a three-dimensional thrombus 
formation model has been described in Pivkin et al. [71] where each platelet was represented 
in a simplified way as a spherical object, while red blood cells were treated using continuum 
submodel describing their density. The model also included an ADP-induced platelet 
activation mechanism. Model simulations accurately reproduced the thrombus growth rate as 
a function of blood velocity obtained in experiments [72].
Fogelson and Guy developed a microscale platelet aggregation model in which individual 
platelets were modeled as fluid-filled closed membranes immersed in a viscous liquid [73]. 
This model allowed for simulations of individual platelet motion and their interactions with 
each other and with surrounding medium. In the model by Mody and King [74], the 
hydrodynamic effects of the oblate spheroidal shape of platelets and the proximity of a wall 
on cell–cell collisions were investigated. Collision time and contact area and collision 
frequency were compared between spherical shape vs. platelet-type oblate shape on one 
hand and presence or not of a proximal bounding wall. The approach used calculation of 
forces and torques acting on each particle in the fluid system (gravity, bond forces, and 
repulsion between two surfaces in close proximity). The study showed that the contact time 
between two platelets during collision close to the wall was greater than the contact time 
during a collision far from the wall. The wall proximity had a greater influence on platelet–
platelet collisions than on sphere–sphere collisions. The method also used Huang and 
Hellums’ mathematical model of the shear-induced platelet aggregation [75–77], where high 
shear resulted in increased platelet aggregation.
Leiderman and Fogelson [78] described a model of blood coagulation under flow that 
included coagulation biochemistry, chemical activation, and deposition of platelets, and a 
two-way interaction between fluid dynamics and growth of platelet mass. Expanding on a 
previously published Kuharsky and Fogelson model [79], this approach now described how 
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tissue factor threshold triggered production of thrombin and how the wall shear rate and 
near-wall increased platelet concentration affected thrombus growth. The porous nature of 
the thrombus, allowing for advective and diffusive transport within itself, was also accounted 
for in the extended model. Xu et al. [63, 80–83] proposed a multi-scale model-coupling 
submodels of coagulation reactions, platelet dynamics, and blood flow, where platelets were 
represented as extended objects with fluctuating boundaries based on the cellular Potts 
model [84].
The importance of quantifying transport of coagulation factors within thrombus 
microenvironment was emphasized in Ref. [69]. By combining in vitro experiments and 
continuum-modeling approach of thrombus hydrodynamics, authors showed that both 
diffusivity and advection of blood proteins through the porous thrombus structure affect 
platelet–thrombus interaction and play an essential role in blood clot growth dynamics. 
Following this work, Stalker et al. demonstrated, using mouse injury model, that regional 
platelet-packing density emerged in parallel with differences in intrathrombus molecular 
transport and predicted that these differences affect thrombus growth and stability [85].
Wu et al. [86] presented a three-dimensional multi-scale platelet–blood flow–vessel wall 
interaction model, which combined three biological scales crucial for the early platelet 
aggregation. The model included hybrid cell membrane submodel of platelet elasticity, 
stochastic receptor–ligand binding submodel of cell adhesion kinetics and Lattice 
Boltzmann submodel of blood flow. Adhesion kinetics involved specific receptor–ligand 
pairs, namely vWF-GpIb complexes. At subcellular level, to simulate vWF–GpIb and GpIb-
vWF–GpIbαbinding, individual molecules were represented by elastic springs. This was 
justified by the demonstration that the receptor–ligand binding is probabilistic in nature. 
Individual filaments of the cytoskeleton network of platelet membrane were modeled as 
coarse-grained harmonic potentials. At cellular level, a novel continuum description of the 
cell membrane was used. The subcellular and cellular components were integrated by 
distributing GpIbα receptors over verticies of the cytoskeleton network and by 
superimposing the lipid bilayer and the network. The model allowed investigation of how 
platelet stiffness, GPIb receptor expression, and platelet–platelet interaction affect platelet–
wall adhesion quantified in terms of platelet pause time. To reduce the computational time 
cost, the model was implemented on graphical processing units (GPUs) computer cluster. 
Predictive simulations revealed that platelet deformation, interactions between platelets in 
the vicinity of the vessel wall, as well as the number of functional GPIbα platelet receptors 
played significant roles in the platelet adhesion to the injury site (Fig. 5.4, from Ref. [86]).
Recently, a multi-scale model was presented in Flamm, Diamond et al. [64, 65, 87], which 
included four components: the fluid flow (using a lattice Boltzmann method), the transport 
of soluble substances (using convection–diffusion–reaction equations), motion and binding 
of platelets leading to their deposition (using a lattice kinetic Monte Carlo algorithm), and 
the activation state of each platelet (using a neural network for cellular signaling). A 
pairwise agonist scanning approach had been found to allow handling of large datasets of 
measured calcium mobilization to predict an individual’s platelet responses to pairwise 
combinations of ADP (which activates P2Y1/P2Y12 receptors), U46619 (which has 
properties similar to Thromboxane A2), and convulxin (which activates GPVI receptor to 
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collagen). A neural network for cellular signaling was used to predict patient-specific 
responses to drugs. The resulting simulations were compared with experimental results in a 
system using blood flowing on collagen in microfluidic devices at different shear rates. The 
simulations were used to predict the individual’s drug sensitivity to cyclooxygenase (COX) 
inhibitors and P2Y1 receptor antagonists in three different blood donors.
Perspective and Conclusions
Increasing and organizing our knowledge on platelet–vessel wall interactions and combining 
it with novel multi-scale computational models to test new biological hypothesis will help 
devise treatments for human disease where excessive thrombosis occurs, while attempting to 
minimize the risk of bleeding. Moreover, platelets and vessels are not only implicated in 
“pure” thrombotic states and inflammatory disease but also in other pathological processes 
such as cancer and metastases. Furthermore, how both platelets and blood vessels may 
contribute to tumor growth and tumor dissemination can be by itself a part of a systems 
approach to cancer biology. Relying only on in vivo studies is impractical and time 
consuming. Genetic knockout animal models have their own limits, as nonhuman animals’ 
biology differs from human biology in many aspects, and a complete functional knockout 
might not yield information on certain conditions, where a dosage effect or a mutated state 
might be the actual determinant pathogenesis. While hypothesis-based experiments are 
being performed, concomitantly developing and refining multi-scale models and running 
simulations on powerful computer clusters will enable biomedical community to accelerate 
testing of new therapeutic targets. Systems biology is thus becoming a novel empowering 
tool to devise new less toxic treatments more efficiently and economically.
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Platelets and vessel walls interact in multiple ways. Platelets and vessel wall cells express 
adhesion molecules, surface receptors, and release substances that initiate or regulate 
cascading thrombosis events. Matrix components of the vessel wall, when blood flow is 
exposed through a damaged endothelium, also elicit clotting reactions from blood cells. 
Moreover, blood cells and endothelial cells also produce microparticles and microvesicles 
that carry procoagulant activity
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Platelets express a diversity of cell surface receptors and chemical substances that interact 
with the vessel wall components during hemostasis. Downstream signaling events take place 
that involve phospholipid signalization, Ca2+ flux, calpain activation, cAMP- and cGMP-
level modulation, cytoskeletal players and their modulators and diverse kinases. Many of 
these pathways intersect or interact with each other in a complex manner
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Systems approach to hemostasis control by platelet–blood vessel interaction. A highly 
informative approach is based on multi-scale analysis of human bleeding disorders at 
biochemical, molecular, genetic, and organismal levels
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Simulated deformations of platelet structure during adhesion to the vessel wall for platelets 
stiffnesses of a 2.5 kPa and b 25 kPa. c The effect of platelet membrane stiffness on the 
platelet pause time. (Originally published in Ref [86] Open Access: http://
rsta.royalsocietypublishing.org/content/372/2021/20130380.long)
Chen et al. Page 16
Adv Exp Med Biol. Author manuscript; available in PMC 2017 March 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
